0002040475false
0002040475
2026-10-29
2026-10-29
0002040475
us-gaap:CapitalUnitsMember
2026-10-29
2026-10-29
0002040475
us-gaap:CommonStockMember
2026-10-29
2026-10-29
0002040475
us-gaap:RightsMember
2026-10-29
2026-10-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2026
DRUGS MADE IN AMERICA ACQUISITION II CORP. |
(Exact name of registrant as specified in its charter) |
Cayman Islands | | 001-42863 | | 98-1815624 |
State or other jurisdiction of incorporation | | Commission File Number | | IRS Employer Identification No. |
420 Lexington Avenue, Suite 1402, New York, NY10170
(Address of principal executive offices, including zip code)
646-726-7074
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☒ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Units, each consisting of one Ordinary Share and one Right to receive one-tenth (1/10) of one Ordinary Share | | DMIIU | | The Nasdaq Stock Market LLC |
Ordinary Shares, par value $0.0001 per share | | DMII | | The Nasdaq Stock Market LLC |
Rights, each entitling the holder to receive one-tenth (1/10) of one Ordinary Share | | DMIIR | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
As previously disclosed in the Current Reports on Form 8-K filed on March 17, 2026 and April 3, 2026, Drugs Made in America Acquisition II Corp. (the "Company") and Tal Alpha Yezum Vekidum Asakim (2003) Ltd. (the "Investor") are parties to the Definitive Investment and Sponsor Transition Agreement dated March 23, 2026 and effective March 24, 2026 (the "Agreement"). Under the Agreement, the Investor committed $1,400,000 of convertible notes financing to the Company (the "Convertible Notes Financing"). The Investor previously funded $450,000 through an unsecured convertible note in the principal amount of $150,000 issued on March 11, 2026 (the "Bridge Note") and an Interim Convertible Note in the principal amount of $300,000 issued on March 30, 2026 (the "Second Note").
On November 6, 2026, the Investor funded a further $250,000 under the Convertible Notes Financing, and the Company has received those funds. Following this installment, $700,000 of the Convertible Notes Financing has been funded and $700,000 remains available under the Agreement.
It has been agreed between the Company and the Investor that the Bridge Note, the Second Note and the $250,000 installment will be consolidated into a single convertible promissory note in the principal amount of $700,000 (the "Consolidated Note"), which will replace the Bridge Note and the Second Note. The Consolidated Note will mature on June 30, 2027, unless earlier converted, extending the maturities of the Bridge Note and the Second Note, which would otherwise have fallen in December 2026. The Consolidated Note will have the same conversion features as the prior notes: upon completion of a business combination, it may, at the option of the Investor, be converted into shares of the combined entity at a conversion price equal to a 35% discount to the market price of such shares at the time of conversion. The Consolidated Note will represent a direct financial obligation of the Company.
Item 8.01. Other Events.
Preliminary Proposal
On October 29, 2026, the Company delivered to Alpha AI Biotech Group ("Alpha") a preliminary proposal regarding a potential business combination (the "Proposal"). Alpha acknowledged and accepted the Proposal in principle on October 30, 2026.
The Proposal contemplates a pre-money equity valuation of Alpha of $600 million, payable in 60,000,000 ordinary shares of the Company at $10.00 per share. Alpha shareholders could also receive up to 30,000,000 additional ordinary shares as earn-out consideration, in two equal tranches subject to share-price thresholds of $12.50 and $15.00 during the 24 months after closing.
The Proposal is subject to, among other things, satisfactory due diligence, audited financial statements, execution of definitive agreements, and required board, shareholder and regulatory approvals.
Limited Standstill
On November 3, 2026, the Company's Board of Directors approved the Proposal's limited 30-day standstill, which expires on or about December 3, 2026 unless extended or terminated earlier. The standstill restricts only the consummation of a competing transaction; it does not prevent either party from evaluating or negotiating alternatives. The Board's approval of the standstill does not constitute approval of any business combination.
Binding and Nonbinding Terms
The Proposal is a nonbinding expression of interest, except for its confidentiality provisions, the limited standstill and the funding acknowledgment described below.
Working Capital Financing; Relationship of Mr. Tal
In connection with the Proposal, the Investor acknowledged its continuing commitment under the Agreement, including the $250,000 installment funded on November 6, 2026 and described in Item 2.03 above. The Investor's funding commitment is not contingent on approval or closing of the proposed transaction with Alpha.
Alon Izidor Tal, the Chief Executive Officer of the Investor, is also a director of Alpha and acknowledged the Proposal on Alpha's behalf. The Agreement also contains provisions relating to a transition of the Company's sponsor, as described in the Current Report on Form 8-K filed on April 3, 2026. The Company's Board of Directors, which consists entirely of independent directors, was aware of Mr. Tal's relationships with both Alpha and the Investor when it approved the standstill.
No Assurance
No definitive business combination agreement has been executed. There can be no assurance that a definitive agreement will be executed, that the proposed terms will be maintained, that any earn-out shares will become issuable, or that any transaction will be consummated.
Forward-Looking Statements; Additional Information
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements about the proposed business combination with Alpha, its terms and valuation, the potential earn-out consideration, the expected timing of definitive agreements, and the Company's working capital financing. Words such as "may," "will," "expect," "intend," "contemplate," "potential" and similar expressions identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond the Company's control. Actual results may differ materially.
Factors that could cause such differences include, among others: the inability to negotiate or execute definitive agreements; the results of due diligence, including verification of Alpha's assets, ownership, intellectual property and financial statements; changes to the proposed valuation or other terms; the amount of redemptions from the Company's trust account; the failure to obtain required board, shareholder or regulatory approvals; termination of the limited standstill; the availability of working capital financing; potential conflicts of interest, including Mr. Tal's relationships with both Alpha and the Investor; and the risks described in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update these statements, except as required by law.
Additional Information and Where to Find It
If a definitive agreement is executed, the Company [and/or Alpha] intends to file with the SEC [a registration statement on Form S-4 / Form F-4, which will include a proxy statement/prospectus] in connection with the proposed transaction. Shareholders of the Company are urged to read those documents, when available, because they will contain important information about the Company, Alpha and the proposed transaction. Those documents, when filed, will be available free of charge on the SEC's website at www.sec.gov or by directing a request to the Company at 420 Lexington Avenue, Suite 1402, New York, NY 10170.
Participants in the Solicitation
The Company, Alpha and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the Company's shareholders in connection with the proposed transaction. Information about the Company's directors and executive officers is set forth in the Company's filings with the SEC. Additional information regarding the interests of participants, including the interests of Mr. Tal and the Investor, will be included in the proxy statement/prospectus if and when filed.
No Offer or Solicitation
This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or the proposed transaction. It does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DRUGS MADE IN AMERICA ACQUISITION II CORP. | |
| | | |
Date: November 18, 2026 | By: | /s/ Roger E. Bendelac | |
| Name: | Roger E. Bendelac | |
| Title: | Chief Executive Officer | |